Centre for Respiratory Infection, National Heart and Lung Institute, Imperial College London, London W2 1PG, United Kingdom.
Curr Opin Virol. 2013 Aug;3(4):468-74. doi: 10.1016/j.coviro.2013.05.005. Epub 2013 Jun 25.
Respiratory syncytial virus (RSV) is the most important cause of infantile bronchiolitis and a major pathogen in elderly and immunosuppressed persons. Although RSV shows limited antigenic diversity, repeated infections occur throughout life. Vaccine development has been delayed by poor immunogenicity, production issues and the fear of causing enhanced disease. T cells assist in viral clearance, but immune regulation serves to limit these responses and to prevent the exaggerated inflammatory response to RSV infection seen in children with bronchiolitis. Severe RSV disease can therefore be regarded as a dysregulated response to an otherwise trivial infection. Further insights into the role of T cells (including Th17) are needed to enable the rational design of safe, effective vaccines and novel treatments.
呼吸道合胞病毒(RSV)是婴儿细支气管炎的最重要病因,也是老年和免疫抑制人群的主要病原体。尽管 RSV 的抗原多样性有限,但它会在整个生命周期中反复感染。由于免疫原性差、生产问题以及担心引起疾病加重,疫苗的开发一直受到阻碍。T 细胞有助于清除病毒,但免疫调节有助于限制这些反应,并防止细支气管炎患儿中观察到的 RSV 感染引起的过度炎症反应。因此,严重的 RSV 疾病可被视为对原本轻微感染的失调反应。需要进一步深入了解 T 细胞(包括 Th17)的作用,以实现安全、有效的疫苗和新型治疗方法的合理设计。